In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: Results from the leiden MISSION! Acute myocardial infarction treatment optimization program

Catheterization and Cardiovascular Interventions

Volumn 74, Issue 2, 2009, Pages 335-343

  Hassan, Ayman K M ^a,b   Liem, Su San ^a   van der Kley, Frank ^a   Bergheanu, Sandrin C ^a   Wolterbeek, Ron ^a   Bosch, Jan ^c   Bootsma, Marianne ^a   Zeppenfeld, Katja ^a   van der Laarse, Arnoud ^a   Atsma, Douwe E ^a   Jukema, J Wouter ^a   Schalij, Martin J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ASSIUT UNIVERSITY   (Egypt)

^c Regional Ambulance Service Hollands Midden   (Netherlands)

Author keywords

IIb IIIa antagonist; Percutaneous coronary intervention; Reperfusion; ST segment elevation myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GENDER BIAS; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART SCINTISCANNING; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; ST SEGMENT ELEVATION;

AGED; AMBULANCES; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; CLINICAL PROTOCOLS; CORONARY ANGIOGRAPHY; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL PERFUSION IMAGING; MYOCARDIUM; NETHERLANDS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PROGRAM EVALUATION; PROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY; VENTRICULAR FUNCTION, LEFT;

EID: 70349556405     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21980     Document Type: Article

References (28)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
2. Kiernan TJ, Ting HH, Gersh BJ. Facilitated percutaneous coronary intervention: Current concepts, promises, and pitfalls. Eur Heart J 2007;28:1545-1553.
3. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996;348:771-775.
4. Gersh BJ, Stone GW, White HD, Holmes DR. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: Is the slope of the curve the shape of the future? JAMA 2005;293:979-986.
5. ASSENT-4 investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): Randomised trial. Lancet 2006;367:569-578.
6. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358:2205-2217.
7. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: Quantitative review of randomised trials. Lancet 2006;367:579-588.
8. Sinno MCN, Khanal S, Al-Mallah MH, Arida M, Weaver WD. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis of randomized clinical trials. Am Heart J 2007;153:579-586.
9. Liem SS, van der Hoeven BL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J, Viergever EP, van Rees C, Padmos I, Sedney MI, van Exel HJ, Verwey HF, Atsma DE, van der Velde ET, Jukema JW, van der Wall EE, Schalij MJ. MISSION!: Optimization of acute and chronic care for patients with acute myocardial infarction. Am Heart J 2007;153:14.e1-14.e11.
10. The TIMI Study Group. The thrombolysis in myocardila infarction (TIMI) trial. Phase I findings. N Engl J Med 1985;312:932-936.
11. Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, Wallentin L, Van de WF, Verheugt F, Armstrong PW. Aborted myocardial infarction in patients with ST-segment elevation: Insights from the assessment of the safety and efficacy of a new thrombolytic regimen-3 trial electrocardiographic substudy. J Am Coll Cardiol 2004;44:38-43.
12. Bruschke AV, van der Laarse A, van der Wall EE. Assessment of the size of acute myocardial infarction. I. Biochemical methods. Cleve Clin J Med 1990;57:547-550.
13. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T, Hirai J, Saga T, Yamamoto S, Tonami N. Quantitative rest technetium-99m tetrofosmin imaging in predicting functional recovery after revascularization: Comparison with rest-redistribution thallium-201. J Am Coll Cardiol 1997;29:1226-1233.
14. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.
15. Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials. Am Heart J 2002;144:981-986.
16. Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: Results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv 2006;68:218-224.
17. Bellandi F, Maioli M, Leoncini M, Toso A, Dabizzi RP. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int J Cardiol 2006;108:36-42.
18. Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, Hodl R, Gaul G, Bonner G, Wojta J, Laggner A, Glogar D, Huber K. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - Results of the Austrian multi-centre randomized ReoPro-BRIDGING study. Eur Heart J 2004;25:2125-2133.
19. Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol 2007;49:1517-1524.
20. Rakowski T, Zalewski J, Legutko J, Bartus S, Rzeszutko L, Dziewierz A, Sorysz D, Bryniarski L, Zmudka K, Kaluza GL, Dubiel JS, Dudek D. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: A randomized study. Am Heart J 2007;153:360-365.
21. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:533-536.
22. Dudek D, Siudak Z, Janzon M, Birkemeyer R, Aldama-Lopez G, Lettieri C, Janus B, Wisniewski A, Berti S, Olivari Z, Rakowski T, Partyka L, Goedicke J, Zmudka K. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab-EUROTRANSFER Registry. Am Heart J 2008;156:1147-1154.
23. De Luca G, Gibson M, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel M, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, Van't Hof AW. Early Glycoprotein IIb-IIIa inhibitors in Primary angioplasty (EGYPT) cooperation. An individual patients' data meta-analysis. Heart 2008;94:1548-1558.
24. Arntz HR, Schroder JF, Peis K, Schwimmbeck P, Witzenbichler B, Schultheiss HP. Prehospital versus periprocedural administration of abciximab in STEMI: Early and late results from the randomised REOMOBILE-study. Eur Heart J 2003;24:268.
25. van't Hof AW, Ten BJ, Heestermans T, Dill T, Funck RC, van WW, Dambrink JH, Suryapranata H, van HG, Ottervanger JP, Stella P, Giannitsis E, Hamm C. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial. Lancet 2008;372:537-546.
26. Beeres SL, Oemrawsingh PV, Warda HM, Bechan R, Atsma DE, Jukema JW, van der Wall EE, Schalij MJ. Early administration of abciximab in patients with acute myocardial infarction improves angiographic and clinical outcome after primary angioplasty. Catheter Cardiovasc Interv 2005;65:478-483.
27. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA 2005;293:1759-1765.
28. Godicke J, Flather M, Noc M, Gyongyosi M, Arntz HR, Grip L, Gabriel HM, Huber K, Nugara F, Schroder J, Svensson L, Wang D, Zorman S, Montalescot G. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J 2005;150:1015.e11-1015.e17.